{"id":"perindopril-or-perindopril-indapamide","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This action results in vasodilation and a decrease in peripheral resistance, which in turn reduces blood pressure and heart workload. Additionally, ACE inhibitors like perindopril have been shown to have protective effects on the kidneys and heart.","oneSentence":"Perindopril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, thereby reducing blood pressure and heart workload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:24.012Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT04040634","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-08","conditions":"Diabetes Mellitus, High Blood Pressure, Cardiovascular Diseases","enrollment":9476},{"nctId":"NCT05780710","phase":"NA","title":"OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake","status":"RECRUITING","sponsor":"Aktiia SA","startDate":"2023-06-29","conditions":"Hypertension","enrollment":35},{"nctId":"NCT05820880","phase":"PHASE3","title":"Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2019-05-06","conditions":"Hypertension","enrollment":532},{"nctId":"NCT04647292","phase":"PHASE2","title":"European Blood Pressure Intensive Control After Stroke","status":"RECRUITING","sponsor":"University College Dublin","startDate":"2024-05-02","conditions":"Ischemic Stroke, Transient Ischemic Attack","enrollment":142},{"nctId":"NCT06275763","phase":"PHASE4","title":"Optimal Medical Treatment of Difficult-to-treat Hypertension","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2023-10-20","conditions":"Hypertension","enrollment":2500},{"nctId":"NCT04036409","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients","status":"UNKNOWN","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-05","conditions":"Ischemic Stroke, Blood Pressure, Cognitive Impairment","enrollment":4369},{"nctId":"NCT05940909","phase":"PHASE1","title":"Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2023-06-24","conditions":"Bioequivalence","enrollment":50},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT03246555","phase":"PHASE3","title":"Fimasartan in the Senior Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-07-15","conditions":"The Elderly (≥ 70 Years) With Essential Hypertension","enrollment":241},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2543,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Perindopril or Perindopril/Indapamide","genericName":"Perindopril or Perindopril/Indapamide","companyName":"Boryung Pharmaceutical Co., Ltd","companyId":"boryung-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Perindopril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, thereby reducing blood pressure and heart workload. Used for Hypertension, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}